Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

NICE指南草案不推荐贝伐珠单抗/卡培他滨治疗乳腺癌

2012-04-20 卢秀玲 爱唯医学网

贝伐珠单抗卡培他滨乳腺癌NICE
关注

       英国临床优化研究所(NICE)日前表示，将不会建议贝伐珠单抗联合卡培他滨治疗进展性转移性乳腺癌。在4月18日发布的新指南草案中，NICE指出，支持这种联合治疗的证据不足。目前已有2种含贝伐珠单抗的方案被欧盟批准作为进展性转移性乳腺癌的一线治疗，本次被NICE否定的方案是其中之一。        

       英国临床优化研究所(NICE)日前表示，将不会建议贝伐珠单抗联合卡培他滨治疗进展性转移性乳腺癌。在4月18日发布的新指南草案中，NICE指出，支持这种联合治疗的证据不足。目前已有2种含贝伐珠单抗的方案被欧盟批准作为进展性转移性乳腺癌的一线治疗，本次被NICE否定的方案是其中之一。

贝伐珠单抗联合卡培他滨
 
       罗氏的贝伐珠单抗(阿瓦斯汀)是一种人源化单克隆抗体，可阻断血管内皮生长因子，从而减少肿瘤的血供。美国食品药品管理局(FDA)认为风险-收益比率不理想，已于2011年11月撤销了贝伐珠单抗的乳腺癌适应证。但欧洲药品管理局(EMA)并未附和FDA。贝伐珠单抗已在欧洲被批准与紫杉醇或卡培他滨(当紫杉醇被认为不适用时)联用，用于治疗进展性转移性乳腺癌。而在2011年2月，NICE驳回了贝伐珠单抗联合紫杉醇用于该适应证的申请。
 
       在宣布有关贝伐珠单抗联合卡培他滨的决定时，NICE表示不确定RIBBON-1的总生存收益结果。RIBBON-1是一项随机对照试验，共招募1,237例进展性乳腺癌女性患者，其中615例患者被随机分入卡培他滨+贝伐珠单抗组或卡培他滨+安慰剂组。尽管试验结果显示，与卡培他滨单药治疗相比，卡培他滨+贝伐珠单抗可使无进展生存期延长2.9个月，但这一收益能否转化为总生存期的改善却并不确定，因为在该试验的开放性进展后阶段中有很多患者从单药治疗转为联合治疗。
 
       NICE还指出，该试验未采集生活质量方面的数据，而且贝伐珠单抗+卡培他滨组的严重不良反应发生率高于卡培他滨+安慰剂组(36.6% vs. 22.9%)。“此外，高血压、蛋白尿、感觉神经病变和静脉血栓栓塞事件在贝伐珠单抗+卡培他滨组中更多见。因此，委员会的结论是，贝伐珠单抗+卡培他滨的毒性特征逊于卡培他滨+安慰剂。”
 
       最后还有费用的问题。生产商提出的贝伐珠单抗+卡培他滨的最佳病例边际成本-效益比率(ICER)为花费82,000英镑(约合900,000元人民币)可获得1个质量调整生命年(QALY)，而且这还只是单个亚组的数据。贝伐珠单抗的ICER远远超出了NICE认为合理的成本-效益范围。贝伐珠单抗通过静脉注射给药，每3周注射15 mg/kg，每例患者的平均每月费用约为3,689英镑(约合37,300元人民币)。 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954783, encodeId=886b1954e83d8, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 20 20:58:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288896, encodeId=0d601288896e9, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293478, encodeId=f83712934e81c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476915, encodeId=027c14e691506, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-11-20 仁医06

    #贝伐珠#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1954783, encodeId=886b1954e83d8, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 20 20:58:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288896, encodeId=0d601288896e9, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293478, encodeId=f83712934e81c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476915, encodeId=027c14e691506, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-04-22 fusion

    #NICE#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1954783, encodeId=886b1954e83d8, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 20 20:58:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288896, encodeId=0d601288896e9, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293478, encodeId=f83712934e81c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476915, encodeId=027c14e691506, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-04-22 w363522449

    #卡培他滨#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1954783, encodeId=886b1954e83d8, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 20 20:58:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288896, encodeId=0d601288896e9, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293478, encodeId=f83712934e81c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476915, encodeId=027c14e691506, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Apr 22 13:58:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-04-22 sunrural_42825359

    #贝伐#

    0

相关资讯

JCO:贝伐珠单抗+CP未改善黑色素瘤预后

　BEAM，一项随机Ⅱ期临床研究显示，联合贝伐珠单抗与单纯CP（卡铂加紫杉醇）方案化疗相比，未能显著改善转移性黑色素瘤患者预后。文章11月30日在线发表于《临床肿瘤学杂志》（J Clin Oncol）。 原始文献: Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H,

贝伐珠单抗缓解难治性卵巢颗粒细胞瘤患者的症状

引言        近期对于贝伐珠单抗用于卵巢恶性肿瘤的研究集中在上皮恶性肿瘤中[1]。关于贝伐珠单抗用于治疗性索肿瘤，如卵巢颗粒细胞瘤的潜在作用未有评估。在此，我们报道一例难治性卵巢颗粒细胞瘤患者经贝伐珠单抗治疗后腹水症状得到缓解。 病例介绍       

EJC：贝伐珠单抗与胃肠穿孔相关但可控

　　一些随机对照研究（RCT）表明，对于接受氟尿嘧啶为基础化疗的转移性结直肠癌患者，加用贝伐珠单抗可延长其总生存期和无进展生存期；但1%～2%的患者会发生胃肠穿孔（GIP）。 　　美国学者近期在线发表于《欧洲癌症杂志》（European Journal of Cancer）的一项基于社区的大型观察性队列研究表明，GIP发生率与RCT结果一致，但大部分GIP通过手术干预可成功得到控制。 　　该研

贝伐珠单抗与转移性结直肠癌患者ATE有关

来源：医学论坛网 　　《肿瘤学年鉴》（Ann Oncol）近期发表的一项研究表明，贝伐珠单抗治疗与转移性结直肠癌动脉血栓栓塞形成（ATE）风险较高有关，但在老年患者或伴有ATE病史或血管风险因素的患者中，贝伐珠单抗的安全性并不显著更差。此外，研究未能在接受贝伐单抗的患者中证明阿司匹林对ATE的预防作用。 　　该研究来自MAX研究的471例转移性结直肠癌患者的3、4或5级ATE事件和其

Baidu
map
Baidu
map
Baidu
map